热线电话:+86 512 6799 8818

在线咨询

TOP

*姓名

*电话

邮箱

咨询内容

*验证码

联系销售


Sales Image

联系销售助理


Sales Assistant Image

联系PM


PM Image
Consult Now
GentleGen's affinity testing technology: How to choose ELISA, BLI, and SPR?
2026-09-08
GentleGen's affinity testing technology: How to choose ELISA, BLI, and SPR?
This article provides an in-depth analysis of the principles and application stages of three affinity detection technologies—ELISA, BLI, and SPR. It concludes that ELISA is suitable for high-throughput primary screening, BLI serves as a bridge for kinetic analysis, and SPR is the gold standard for regulatory submission. GentleGen offers a full-platform service to match the needs at every stage of antibody development.
View More
GentleGen shines on the "Maker China" arena, reshaping the paradigm of biopharmaceutical R&D with the power of AI4S
2026-08-28
GentleGen shines on the "Maker China" arena, reshaping the paradigm of biopharmaceutical R&D with the power of AI4S
GentleGen Shines at the 11th "Maker in China" SME Innovation and Entrepreneurship Competition, Winning the Top 100 Excellence Award with a Score of 86.41. Dedicated to the AI4S (AI for Science) era, GentleGen leverages automation and intelligence to significantly shorten R&D timelines and reduce overall costs in antibody development.
View More
The "Golden Combination" of affinity testing: How does GentleGen's BLI technology balance speed and accuracy?
2026-08-28
The "Golden Combination" of affinity testing: How does GentleGen's BLI technology balance speed and accuracy?
How does BLI really work in antibody drug discovery? This article breaks down the logic and introduces the "golden combination" strategy—single‑point screening for speed, multi‑concentration KD for precision. It's the smart way to balance throughput and accuracy. And with GentleGen's fully automated platform, you get seamless one‑stop affinity measurement services, from initial screening to full‑scale kinetic profiling.
View More
From "passive fitting" to "autonomous exploration": interpreting the bioRxiv closed-loop AI paper and seeing how GentleGen High-throughput Upper Clearing accelerates the DBTL cycle
2026-08-28
From "passive fitting" to "autonomous exploration": interpreting the bioRxiv closed-loop AI paper and seeing how GentleGen High-throughput Upper Clearing accelerates the DBTL cycle
This article takes you inside the PRAXIS system—a breakthrough published on bioRxiv by Duke and Harvard researchers. PRAXIS is a verifiable AI agent framework for biological research, driven by literature learning and case distillation. Here’s how it works: AI designs enzyme variants autonomously, robots run the experiments, and data streams back in real time to inform the next iteration—closing the loop from design to experiment to learning. GentleGen’s high‑throughput supernatant expression services are built to power exactly this kind of Design‑Build‑Test‑Learn (DBTL) cycle.
View More
Oligonucleotide modification and delivery: For those who know the field, all that's missing is this GentleGen summary of the decision checklist
2026-08-28
Oligonucleotide modification and delivery: For those who know the field, all that's missing is this GentleGen summary of the decision checklist
Navigating the complex choices of modification and delivery in small nucleic acid drug development? This article cuts through the noise—breaking down when to use PS, 2′‑OMe, LNA, and other chemical modifications, how to pair them with delivery systems like GalNAc and LNPs, and offering a clear decision‑making checklist tailored to each stage of your R&D journey.
View More
A single article tackling the "three musketeers" of the gene knockdown world: How to choose RNAi, CRISPRi, and ASO?
2026-08-27
A single article tackling the "three musketeers" of the gene knockdown world: How to choose RNAi, CRISPRi, and ASO?
This article takes a deep dive into the “big three” of gene knockdown—RNAi, CRISPRi, and ASO—covering how they work, where they shine, and where they fall short. RNAi delivers fast, cost‑effective results; CRISPRi excels at durable silencing of nuclear lncRNAs; and ASO can target both cytoplasmic and nuclear RNAs. GentleGen provides integrated one‑stop gene knockdown services to accelerate your discovery.
View More
[Client Article Interpretation] New "force-bone" coupling switch in bone remodeling: Discovery of the Piezo1-ZBP1 pathway and validation of gene manipulation tools
2026-08-14
[Client Article Interpretation] New "force-bone" coupling switch in bone remodeling: Discovery of the Piezo1-ZBP1 pathway and validation of gene manipulation tools
This study reveals that the mechanosensitive channel Piezo1 in macrophages converts mechanical stimuli into inflammatory bone resorption via the ZBP1 signaling axis, establishing a novel molecular switch for bone remodeling. GentleGen provided lentiviral packaging services for this research, supporting the validation of gene manipulation tools.
View More
GentleGen Frontier Focus: By 2026, sgRNA will evolve from a "navigator" to an "operating system" for gene editing.
2026-08-10
GentleGen Frontier Focus: By 2026, sgRNA will evolve from a "navigator" to an "operating system" for gene editing.
In 2026, sgRNA has achieved a dual breakthrough: multiplexed sgRNA-mediated协同 targeting has reached >99% efficiency, chemical modifications have fully armored guide RNAs, while the TDO mechanism has revealed a new source of off-target effects, and ΨDNA has shattered the dogma that “guides must be RNA.” sgRNA is evolving from a mere navigation device for gene scissors into the core control layer of the entire editing system.
View More
Multi-point breakthroughs in siRNA extrahepatic delivery technology by 2026—GentleGen's full-chain technical support
2026-08-10
Multi-point breakthroughs in siRNA extrahepatic delivery technology by 2026—GentleGen's full-chain technical support
In 2026, the PNP platform received Phase II clinical validation, IVSA demonstrated the potential to transform the liver into a “biopharmaceutical factory,” and lipid‑siRNA conjugates achieved breakthroughs in crossing the blood–brain barrier—marking multiple advances in extrahepatic siRNA delivery. GentleGen provides end‑to‑end technical support covering everything from sequence design to high‑throughput screening, helping the field move beyond the question of “whether” extrahepatic delivery is possible to “how” to do it better.
View More
When AI can mass-produce antibodies, what is the core bottleneck?
2026-07-31
When AI can mass-produce antibodies, what is the core bottleneck?
The past 20+ years have seen dramatic shifts in biopharma and synthetic biology. New drug modalities—from small molecules and antibodies to cell and gene therapies—keep emerging. But a single challenge endures: how do we efficiently get to high‑quality leads?
View More
12345
Pre-sales consulting

Pre-sales consulting

A more reliable solution for your needs.
Download

Download

Welcome to our product library.
Sales network

Sales network

Complete sales and service network to ensure product quality.
Event Promotions

Event Promotions

Add to cart now and enjoy this shopping extravaganza!